Scholar Rock Holding Corporation

Scholar Rock Holding Corporationverified

SRRK

Price:

$27.67

Market Cap:

$2.50B

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients s...[Read more]

Industry

Biotechnology

IPO Date

2018-05-25

Stock Exchange

NASDAQ

Ticker

SRRK

The Enterprise Value as of November 2024 (TTM) for Scholar Rock Holding Corporation (SRRK) is 2.47B

According to Scholar Rock Holding Corporation’s latest financial reports and current stock price. The company's current Enterprise Value is 2.47B. This represents a change of 130.25% compared to the average of 1.07B of the last 4 quarters.

Scholar Rock Holding Corporation (SRRK) Historical Enterprise Value (quarterly & annually)

How has SRRK Enterprise Value performed in the past?

The mean historical Enterprise Value of Scholar Rock Holding Corporation over the last ten years is 658.15M. The current 2.47B Enterprise Value has changed 37.48% with respect to the historical average. Over the past ten years (40 quarters), SRRK's Enterprise Value was at its highest in in the March 2021 quarter at 1.74B. The Enterprise Value was at its lowest in in the June 2022 quarter at -3347067.92.

Quarterly (TTM)
Annual

Average

658.15M

Median

418.78M

Minimum

222.11M

Maximum

1.53B

Scholar Rock Holding Corporation (SRRK) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Scholar Rock Holding Corporation Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 318.23%

Maximum Annual Enterprise Value = 1.53B

Minimum Annual Increase = -44.09%

Minimum Annual Enterprise Value = 222.11M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
20231.53B201.99%
2022505.61M-34.86%
2021776.14M-44.09%
20201.39B318.23%
2019331.95M35.49%
2018245.00M10.30%
2017222.11M-17.48%

Scholar Rock Holding Corporation (SRRK) Average Enterprise Value

How has SRRK Enterprise Value performed in the past?

The current Enterprise Value of Scholar Rock Holding Corporation (SRRK) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

936.21M

5-year avg

905.78M

10-year avg

658.15M

Scholar Rock Holding Corporation (SRRK) Enterprise Value vs. Peers

How is SRRK’s Enterprise Value compared to its peers?

Scholar Rock Holding Corporation’s Enterprise Value is greater than TCR2 Therapeutics Inc. (49.64M), less than Revolution Medicines, Inc. (9.07B), greater than Black Diamond Therapeutics, Inc. (159.92M), greater than Atreca, Inc. (-8620212.00), greater than Passage Bio, Inc. (38.72M), greater than Monte Rosa Therapeutics, Inc. (478.04M), greater than Design Therapeutics, Inc. (258.23M), greater than Werewolf Therapeutics, Inc. (139.97K), greater than Ikena Oncology, Inc. (47.83M), greater than Stoke Therapeutics, Inc. (501.96M), greater than IDEAYA Biosciences, Inc. (2.15B), greater than AnaptysBio, Inc. (909.29M), greater than MeiraGTx Holdings plc (448.89M), greater than Keros Therapeutics, Inc. (1.86B), greater than Homology Medicines, Inc. (-103303255.00), less than Avidity Biosciences, Inc. (4.68B), greater than IGM Biosciences, Inc. (902.82M), less than Cerevel Therapeutics Holdings, Inc. (8.24B), greater than Cullinan Oncology, Inc. (810.70M), greater than Mineralys Therapeutics, Inc. (603.45M), greater than Relay Therapeutics, Inc. (867.37M), greater than Pliant Therapeutics, Inc. (860.85M), greater than Arvinas, Inc. (1.76B),

Build a custom stock screener for Scholar Rock Holding Corporation (SRRK) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Scholar Rock Holding Corporation using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Scholar Rock Holding Corporation (SRRK) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Scholar Rock Holding Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Scholar Rock Holding Corporation's Enterprise Value?

What is the highest Enterprise Value for Scholar Rock Holding Corporation (SRRK)?

What is the 3-year average Enterprise Value for Scholar Rock Holding Corporation (SRRK)?

What is the 5-year average Enterprise Value for Scholar Rock Holding Corporation (SRRK)?

How does the current Enterprise Value for Scholar Rock Holding Corporation (SRRK) compare to its historical average?